_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502568548,7/12/2014 08:01:11,,1321261001,7/12/2014 08:01:03,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detected,da,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 08:05:13,,1321262130,7/12/2014 08:03:45,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,na,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 08:09:38,,1321263488,7/12/2014 08:09:18,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],was detected,na,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 08:18:18,,1321265827,7/12/2014 08:16:42,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],IL 4 detected patients with MIGRAINE HEADACHES with TENSION TYPE HEADACHES,is a,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 08:51:08,,1321276623,7/12/2014 08:50:21,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],was with,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 09:07:00,,1321281907,7/12/2014 09:06:45,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],HEADACHES,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 10:01:38,,1321300282,7/12/2014 10:00:32,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],HEADACHES HEADACHES,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 10:04:17,,1321301124,7/12/2014 10:03:36,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with,none,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 10:04:22,,1321301161,7/12/2014 10:03:43,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE HEADACHES TENSION TYPE HEADACHES,n/a,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 10:22:04,,1321306813,7/12/2014 10:21:29,neodev,1,18517457,GBR,,,86.29.147.112,[OTHER],[OTHER],patients with patients with,Both are types of headaches,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 10:24:14,,1321307634,7/12/2014 10:23:48,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHES HEADACHES,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 10:43:00,,1321313454,7/12/2014 10:41:19,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],and patients with,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 11:08:01,,1321321936,7/12/2014 11:07:35,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[NONE],[NONE],N/A,Two separate types of headaches are being discussed.,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 13:27:07,,1321366407,7/12/2014 13:26:58,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],28.6%,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568548,7/12/2014 13:44:09,,1321372240,7/12/2014 13:43:57,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,93,44,115,62,-1,RO-has_definitional_manifestation,904839-FS1,IL 4 was detected in 17.1% of patients with MIGRAINE HEADACHES and in 28.6% of patients with TENSION TYPE HEADACHES,TENSION TYPE HEADACHES,MIGRAINE HEADACHES
502568549,7/12/2014 07:16:02,,1321246234,7/12/2014 07:14:24,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],associated with increased GASTROINTESTINAL BLEEDING in patients with PV,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 07:37:05,,1321253270,7/12/2014 07:36:30,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,na,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 08:00:14,,1321260562,7/12/2014 08:00:04,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],dose,da,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 08:44:22,,1321274367,7/12/2014 08:43:36,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 09:06:08,,1321281618,7/12/2014 09:04:56,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 09:22:42,,1321286911,7/12/2014 09:22:18,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 09:58:42,,1321299288,7/12/2014 09:57:44,vivatic,1,25451531,GBR,,,83.67.28.193,[OTHER],[OTHER],associated with in patients with,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 10:12:05,,1321303563,7/12/2014 10:11:28,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],GASTROINTESTINAL BLEEDING PV,n/a,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 10:12:24,,1321303630,7/12/2014 10:12:16,instagc,1,27753923,GBR,,,92.40.74.118,[CAUSES],[CAUSES],GASTROINTESTINAL BLEEDING,n/a,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 10:25:10,,1321307884,7/12/2014 10:24:53,neodev,1,18517457,GBR,,,86.29.147.112,[SYMPTOM],[SYMPTOM],in patients with PV,N/a,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 10:31:53,,1321310046,7/12/2014 10:31:29,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],with,none,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 11:00:41,,1321318999,7/12/2014 11:00:06,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],in patients with,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 11:10:14,,1321322627,7/12/2014 11:09:49,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 11:24:37,,1321327808,7/12/2014 11:24:00,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with increased,N/A,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568549,7/12/2014 11:40:16,,1321332384,7/12/2014 11:39:02,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION] [SIDE_EFFECT] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",associated with increased,n/a,59,102,84,104,1,RO-disease_may_have_finding,902816-FS1,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV
502568550,7/12/2014 07:58:09,,1321259848,7/12/2014 07:58:00,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],Disturbances tracheal,da,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 08:06:39,,1321262617,7/12/2014 08:05:43,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[IS_A],[IS_A],VIRUS,na,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 08:17:32,,1321265568,7/12/2014 08:17:14,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],appear depend,na,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 08:48:05,,1321275581,7/12/2014 08:46:42,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],appear to depend,N/A,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 09:22:28,,1321286836,7/12/2014 09:21:49,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DURING VIRUS INFECTION,N/A,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 10:00:32,,1321299888,7/12/2014 09:59:36,vivatic,1,25451531,GBR,,,83.67.28.193,[SYMPTOM],[SYMPTOM],DURING VIRUS INFECTION,N/A,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 10:02:11,,1321300484,7/12/2014 10:01:35,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MUCOUS TRANSPORT DURING VIRUS INFECTION,n/a,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 10:13:19,,1321303889,7/12/2014 10:13:11,instagc,1,27753923,GBR,,,92.40.74.118,[CAUSES],[CAUSES],MUCOUS TRANSPORT,n/a,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 10:29:25,,1321309312,7/12/2014 10:28:53,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],depend,none,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 11:15:22,,1321324575,7/12/2014 11:14:09,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],MUCOUS TRANSPORT DURING VIRUS INFECTION depend upon the type VIRUS,N/A,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 11:44:04,,1321333493,7/12/2014 11:43:16,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],A respiratory syncytial,n/a,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 13:26:25,,1321366169,7/12/2014 13:26:16,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],depend,N/A,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 13:27:48,,1321366633,7/12/2014 13:27:28,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],VIRUS,n/a,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 13:38:05,,1321370100,7/12/2014 13:37:46,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],depend upon,n/a,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568550,7/12/2014 13:43:42,,1321372072,7/12/2014 13:43:24,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[CAUSES],[CAUSES],respiratory syncytial VIRUS infection.,N/A,49,25,54,64,1,RO-has_causative_agent,903829-FS1,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION
502568551,7/12/2014 07:12:41,,1321245222,7/12/2014 07:11:17,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],FLUOROSIS monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE,N/A,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 07:51:14,,1321257487,7/12/2014 07:50:06,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],effects,na,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 08:57:56,,1321278820,7/12/2014 08:56:41,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[SIDE_EFFECT],[SIDE_EFFECT],effects,n/a,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 09:19:13,,1321285678,7/12/2014 09:18:26,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],adjustments to the FLUORIDE concentration,N/A,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 10:11:20,,1321303346,7/12/2014 10:11:12,instagc,1,27753923,GBR,,,92.40.74.118,[MANIFESTATION],[MANIFESTATION],"enamel secretion,",n/a,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 10:22:44,,1321307042,7/12/2014 10:22:11,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],may occur,none,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 10:27:19,,1321308554,7/12/2014 10:26:49,neodev,1,18517457,GBR,,,86.29.147.112,[CAUSES],[CAUSES],minor adjustments to the,N/a,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 11:01:25,,1321319254,7/12/2014 11:00:42,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],may occur,N/A,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 13:15:53,,1321362727,7/12/2014 13:15:17,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],the effects on,n/a,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 13:24:14,,1321365377,7/12/2014 13:23:10,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],adjustments,n/a,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 13:24:48,,1321365585,7/12/2014 13:24:39,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],concentration,N/A,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 13:47:44,,1321373503,7/12/2014 13:47:35,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,separate,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 13:51:37,,1321374819,7/12/2014 13:50:29,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],effects on of minor adjustments to the concentration,n/a,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 14:02:54,,1321378193,7/12/2014 14:01:43,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],minor adjustments,na,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568551,7/12/2014 14:26:17,,1321385121,7/12/2014 14:25:07,gifthulk,1,21916793,GBR,,,87.113.87.199,[NONE],[NONE],N/A,They are part of separate points and not related within the sentence.,489,242,497,258,-1,RO-has_causative_agent,903790-FS1,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
502568552,7/12/2014 08:01:20,,1321261022,7/12/2014 08:01:12,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],seems,da,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 08:15:08,,1321264889,7/12/2014 08:14:44,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PREVENTS],[PREVENTS],solution,na,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 08:59:18,,1321279244,7/12/2014 08:56:39,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],on the,N/A,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 09:12:23,,1321283650,7/12/2014 09:11:41,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[LOCATION],[LOCATION],on the,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 10:03:06,,1321300764,7/12/2014 10:02:23,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[LOCATION],[LOCATION],PERSPIRATION on the SKIN,N/A,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 10:03:07,,1321300784,7/12/2014 10:02:14,vivatic,1,25451531,GBR,,,83.67.28.193,[LOCATION],[LOCATION],on the,N/A,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 10:09:16,,1321302725,7/12/2014 10:09:06,instagc,1,27753923,GBR,,,92.40.74.118,[PREVENTS],[PREVENTS],significant concentrations nitrite,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 10:13:34,,1321304003,7/12/2014 10:12:56,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PERSPIRATION SKIN,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 10:16:04,,1321304824,7/12/2014 10:15:44,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[LOCATION],[LOCATION],on the,N/A,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 10:24:20,,1321307666,7/12/2014 10:24:01,neodev,1,18517457,GBR,,,86.29.147.112,[LOCATION],[LOCATION],on the SKIN,N/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 11:42:39,,1321333118,7/12/2014 11:40:17,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",concentrations,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 13:09:51,,1321360884,7/12/2014 13:09:33,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],on the,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 13:12:44,,1321361749,7/12/2014 13:12:15,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],PERSPIRATION on the SKIN,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 13:26:47,,1321366311,7/12/2014 13:26:38,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],involved,N/A,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568552,7/12/2014 13:46:15,,1321372995,7/12/2014 13:45:54,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PERSPIRATION on the SKIN,n/a,439,419,443,431,1,RO-has_finding_site,905376-FS1,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION
502568553,7/12/2014 07:25:34,,1321249592,7/12/2014 07:24:51,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],pregnancy preterm birth for,N/A,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 07:53:21,,1321258201,7/12/2014 07:51:56,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],pregnancies with low activity.,na,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 08:12:12,,1321264197,7/12/2014 08:11:44,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],pregnancy,na,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 08:13:41,,1321264581,7/12/2014 08:12:38,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Moderate severe lupus activity ACTIVE LUPUS NEPHRITIS LUPUS pregnancies,associated with,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 08:27:29,,1321269171,7/12/2014 08:26:16,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],Moderate activity in,N/A,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 08:31:08,,1321270503,7/12/2014 08:30:48,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS Estimated preterm birth,n/a,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 09:10:32,,1321283133,7/12/2014 09:09:16,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],LUPUS,N/A,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 09:24:21,,1321287550,7/12/2014 09:23:53,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],LUPUS LUPUS,N/A,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 11:15:55,,1321324748,7/12/2014 11:15:14,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Estimated 30% preterm birth for LUPUS,N/A,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 12:05:57,,1321340664,7/12/2014 12:05:28,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],activity in pregnancy,n/a,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 13:24:56,,1321365623,7/12/2014 13:24:37,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS,n/a,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 13:27:31,,1321366533,7/12/2014 13:27:21,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],Moderate,N/A,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 13:39:39,,1321370617,7/12/2014 13:38:54,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],severe lupus activity in pregnancy,n/a,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 13:41:17,,1321371169,7/12/2014 13:40:45,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],Estimated 30% preterm birth for,n/a,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568553,7/12/2014 13:47:04,,1321373244,7/12/2014 13:46:54,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,118,125,140,130,-1,RO-has_manifestation,906226-FS1,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy ACTIVE LUPUS NEPHRITIS  Estimated 30% preterm birth for LUPUS pregnancies with low activity.,ACTIVE LUPUS NEPHRITIS,LUPUS
502568554,7/12/2014 07:18:52,,1321247145,7/12/2014 07:17:11,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],ANTIARRHYTHMIC action of L PC on REOXYGENATION,N/A,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 08:11:16,,1321263972,7/12/2014 08:10:55,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not correlated,na,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 08:39:30,,1321272974,7/12/2014 08:39:12,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],action of,n/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 08:46:41,,1321275048,7/12/2014 08:44:23,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not correlated,N/A,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 09:04:46,,1321281222,7/12/2014 09:04:19,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],is not correlated,n/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 09:56:26,,1321298500,7/12/2014 09:54:30,vivatic,1,25451531,GBR,,,83.67.28.193,[NONE],[NONE],N/A,It is an action of the drug used for the condition.,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 10:06:06,,1321301724,7/12/2014 10:05:13,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIARRHYTHMIC REOXYGENATION INDUCED ARRHYTHMIAS,n/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 10:13:01,,1321303826,7/12/2014 10:12:52,instagc,1,27753923,GBR,,,92.40.74.118,[TREATS],[TREATS],ANTIARRHYTHMIC REOXYGENATION,n/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 10:32:26,,1321310172,7/12/2014 10:31:55,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,none,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 10:46:22,,1321314441,7/12/2014 10:45:24,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not correlated with,N/A,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 11:01:31,,1321319302,7/12/2014 11:00:00,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[NONE],[NONE],N/A,"It says that it ""is not correlated"", therefore there is no relation between the two.",58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 11:51:52,,1321336194,7/12/2014 11:50:38,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[NONE],[NONE],not,is not correlated with its direct electrophysiological effects studied on normoxic preparations.,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 12:34:45,,1321348433,7/12/2014 12:34:22,neodev,1,18517457,GBR,,,86.29.147.112,[MANIFESTATION],[MANIFESTATION],action of L PC on,N/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 13:07:34,,1321360122,7/12/2014 13:06:29,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],not correlated,n/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568554,7/12/2014 13:13:04,,1321361821,7/12/2014 13:11:46,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIARRHYTHMIC ARRHYTHMIAS,n/a,58,25,91,39,1,RO-may_prevent,907239-FS1,It is concluded that the ANTIARRHYTHMIC action of L PC on REOXYGENATION INDUCED ARRHYTHMIAS is not correlated with its direct electrophysiological effects studied on normoxic preparations.,REOXYGENATION INDUCED ARRHYTHMIAS,ANTIARRHYTHMIC
502568555,7/12/2014 07:21:48,,1321248114,7/12/2014 07:21:14,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],BINGE PROGRAMME BINGE EATING,N/A,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 07:39:54,,1321254028,7/12/2014 07:39:14,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],subjects affected,na,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 08:19:38,,1321266256,7/12/2014 08:19:21,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],patients enrolled into,na,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 08:35:09,,1321271732,7/12/2014 08:32:33,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],affected by,N/A,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 08:38:25,,1321272635,7/12/2014 08:37:30,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[TREATS],[TREATS],a WEEK PROGRAMME subjects affected BINGE EATING,n/a,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 09:19:40,,1321285867,7/12/2014 09:19:15,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],for subjects affected by,N/A,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 10:11:57,,1321303526,7/12/2014 10:11:49,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],BINGE PROGRAMME,n/a,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 10:14:56,,1321304447,7/12/2014 10:14:06,vivatic,1,25451531,GBR,,,83.67.28.193,[TREATS],[TREATS],for subjects affected by,N/A,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 10:19:19,,1321305770,7/12/2014 10:18:31,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],20 WEEK BINGE PROGRAMME BINGE EATING,n/a,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 10:23:18,,1321307262,7/12/2014 10:22:57,neodev,1,18517457,GBR,,,86.29.147.112,[TREATS],[TREATS],for subjects affected by,N/a,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 10:30:22,,1321309659,7/12/2014 10:29:49,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,none,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 10:54:12,,1321316911,7/12/2014 10:53:26,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],affected by,N/A,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 12:46:08,,1321352202,7/12/2014 12:45:48,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],for subjects affected by,n/a,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 13:38:53,,1321370389,7/12/2014 13:38:05,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for subjects affected by,n/a,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568555,7/12/2014 13:45:06,,1321372579,7/12/2014 13:44:53,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subjects affected by,N/A,219,170,231,193,-1,RO-has_definitional_manifestation,904800-FS1,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME
502568556,7/12/2014 07:54:18,,1321258530,7/12/2014 07:53:25,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[SYMPTOM],[SYMPTOM],found at operation to have,na,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 08:00:43,,1321260803,7/12/2014 08:00:36,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],old,da,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 08:41:16,,1321273528,7/12/2014 08:39:13,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],found at,N/A,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 08:42:39,,1321273867,7/12/2014 08:42:16,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CORNEAL NERVES AND HYPERTENSION PARATHYROID HYPERPLASIA PHEOCHROMOCYTOMA,n/a,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 09:47:38,,1321295406,7/12/2014 09:46:56,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 10:04:42,,1321301242,7/12/2014 10:03:38,vivatic,1,25451531,GBR,,,83.67.28.193,[MANIFESTATION],[MANIFESTATION],was found to have,N/A,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 10:14:29,,1321304293,7/12/2014 10:13:55,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found at operation to have,N/A,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 11:03:41,,1321320115,7/12/2014 11:03:01,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],to have,N/A,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 11:13:35,,1321323878,7/12/2014 11:12:22,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],"CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",N/A,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 12:36:35,,1321348956,7/12/2014 12:36:01,neodev,1,18517457,GBR,,,86.29.147.112,[SYMPTOM],[SYMPTOM],with a,N/a,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 13:05:49,,1321359566,7/12/2014 13:03:11,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],found,n/a,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 13:46:28,,1321373119,7/12/2014 13:46:15,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,separate,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 13:48:48,,1321373821,7/12/2014 13:48:07,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],was found at operation to have,n/a,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 14:09:45,,1321380247,7/12/2014 14:09:07,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",found,na,127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568556,7/12/2014 14:26:28,,1321385141,7/12/2014 14:23:24,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[PREVENTS],[PREVENTS],medullary,[PREVENTS],127,226,158,270,1,RO-disease_may_have_finding,902547-FS1,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA
502568557,7/12/2014 07:36:29,,1321253137,7/12/2014 07:35:54,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[SYMPTOM],[SYMPTOM],important clue,na,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 08:01:28,,1321261058,7/12/2014 08:01:21,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],NONTHROMBOCYTIC,da,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 09:02:38,,1321280507,7/12/2014 09:01:17,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],important clue for the diagnosis of,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 09:11:39,,1321283498,7/12/2014 09:11:19,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 10:02:22,,1321300546,7/12/2014 10:01:46,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[SYMPTOM],[SYMPTOM],is an important clue for the diagnosis of,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 10:03:37,,1321300963,7/12/2014 10:03:01,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],NONTHROMBOCYTIC PURPURA HENOCH SCHONLEIN PURPURA,n/a,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 10:15:43,,1321304684,7/12/2014 10:14:57,vivatic,1,25451531,GBR,,,83.67.28.193,[MANIFESTATION],[MANIFESTATION],important clue for the diagnosis of,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 10:18:00,,1321305360,7/12/2014 10:17:12,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[SYMPTOM],[SYMPTOM],important clue diagnosis,n/a,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 10:28:51,,1321309073,7/12/2014 10:28:23,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is,none,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 10:51:54,,1321316133,7/12/2014 10:51:12,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],for the diagnosis,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 11:10:30,,1321322747,7/12/2014 11:10:03,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 13:26:38,,1321366231,7/12/2014 13:26:27,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],diagnosis,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 13:38:23,,1321370171,7/12/2014 13:38:06,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],important clue for the diagnosis,n/a,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 13:45:19,,1321372654,7/12/2014 13:45:07,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],clue for the diagnosis,N/A,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568557,7/12/2014 13:49:12,,1321373965,7/12/2014 13:48:49,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],The appearance of important clue for the diagnosis,n/a,18,84,41,108,-1,RO-has_definitional_manifestation,904727-FS1,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
502568558,7/12/2014 07:41:15,,1321254409,7/12/2014 07:40:38,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[PART_OF],[PART_OF],MONOCLONAL GAMMOPATHY,na,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 08:01:38,,1321261094,7/12/2014 08:01:30,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],biopsies,da,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 08:12:55,,1321264359,7/12/2014 08:12:33,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],characterize significance.,na,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 09:17:38,,1321285222,7/12/2014 09:17:06,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 09:51:45,,1321296704,7/12/2014 09:50:07,vivatic,1,25451531,GBR,,,83.67.28.193,[NONE],[NONE],N/A,They are both treatments.,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 10:08:45,,1321302564,7/12/2014 10:08:36,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],6/CD40 loop,n/a,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 12:04:51,,1321340435,7/12/2014 12:03:30,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],biopsies tested,n/a,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 12:34:18,,1321348257,7/12/2014 12:33:40,neodev,1,18517457,GBR,,,86.29.147.112,[NONE],[NONE],N/a,They are two separate conditions,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 13:12:13,,1321361625,7/12/2014 13:10:52,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],tested WALDENSTROM'S MACROGLOBULINEMIA 6 OF MONOCLONAL GAMMOPATHY,n/a,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 13:14:10,,1321362179,7/12/2014 13:13:28,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],use of the CD40 monoclonal antibody on,n/a,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 13:45:43,,1321372833,7/12/2014 13:45:32,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 13:50:29,,1321374380,7/12/2014 13:49:44,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],biopsies tested undetermined significance.,n/a,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 14:00:59,,1321377617,7/12/2014 14:00:13,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significance.,na,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 14:21:27,,1321383548,7/12/2014 14:20:27,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],to characterize the IL 6/CD40 loop activity in MM.,[MANIFESTATION],417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568558,7/12/2014 14:27:31,,1321385540,7/12/2014 14:26:18,gifthulk,1,21916793,GBR,,,87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],21 of 28 plasma cell dyscrasia,N/A,417,344,445,375,-1,RO-disease_has_finding,901978-FS1,"With the use of the CD40 monoclonal antibody (MoAb) G28 5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL 6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 WALDENSTROM'S MACROGLOBULINEMIA [WM], 2 of 2 plasma cell leukemia [PCL], 6 OF 8 MONOCLONAL GAMMOPATHY of undetermined significance.",6 OF 8 MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
502568559,7/12/2014 07:20:24,,1321247592,7/12/2014 07:19:30,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],BACTERIA development,N/A,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 07:38:27,,1321253661,7/12/2014 07:37:06,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluate the effect,na,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 08:00:02,,1321260534,7/12/2014 07:59:52,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],study,da,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 08:17:13,,1321265449,7/12/2014 08:16:56,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],effect,na,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 08:36:25,,1321272082,7/12/2014 08:35:46,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],the effect of,N/A,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 08:42:15,,1321273776,7/12/2014 08:41:55,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROBIOTIC BACTERIA CARIES,n/a,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 09:06:15,,1321281671,7/12/2014 09:05:32,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 10:13:06,,1321303850,7/12/2014 10:12:46,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PREVENTS],[PREVENTS],on,N/A,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 10:14:04,,1321304159,7/12/2014 10:13:26,vivatic,1,25451531,GBR,,,83.67.28.193,[PREVENTS],[PREVENTS],effect of milk supplemented with,N/A,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 10:18:26,,1321305505,7/12/2014 10:17:37,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",PROBIOTIC BACTERIA CARIES,n/a,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 10:26:37,,1321308324,7/12/2014 10:26:09,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 10:53:25,,1321316637,7/12/2014 10:52:39,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[PREVENTS],[PREVENTS],evaluate the effect,N/A,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 10:55:42,,1321317358,7/12/2014 10:53:25,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[NONE],[NONE],N/A,They are talking about two separate issues and thus probiotic bacteria has no link with caries.,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 11:23:59,,1321327629,7/12/2014 11:23:16,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],evaluate the effect on,N/A,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568559,7/12/2014 13:08:17,,1321360364,7/12/2014 13:07:36,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[SIDE_EFFECT],[SIDE_EFFECT],evaluate the effect,n/a,75,110,93,116,-1,RO-has_causative_agent,903916-FS1,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES
502568560,7/12/2014 07:58:31,,1321259960,7/12/2014 07:58:20,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],and SYSTEMIC LUPUS,da,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 08:09:39,,1321263490,7/12/2014 08:08:29,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE,associated with,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 08:14:21,,1321264729,7/12/2014 08:13:45,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[NONE],[NONE],na,No relation??,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 08:33:02,,1321271119,7/12/2014 08:32:36,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the,n/a,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 09:11:54,,1321283549,7/12/2014 09:11:13,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS,N/A,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 10:08:18,,1321302456,7/12/2014 10:07:39,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SYSTEMIC LUPUS ERYTHEMATOSUS: HOPKINS LUPUS COHORT PERSPECTIVE,n/a,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 10:21:00,,1321306398,7/12/2014 10:20:28,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],the,none,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 10:51:33,,1321315990,7/12/2014 10:49:16,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[PART_OF],[PART_OF],the,N/A,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 13:10:17,,1321361017,7/12/2014 13:09:52,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],the [Editorial.,n/a,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 13:15:16,,1321362506,7/12/2014 13:14:36,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],the,n/a,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 13:44:51,,1321372514,7/12/2014 13:44:38,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,broken sentence,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 13:53:13,,1321375236,7/12/2014 13:52:47,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE,n/a,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 14:10:49,,1321380518,7/12/2014 14:09:47,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],and the,na,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 14:29:06,,1321385979,7/12/2014 14:27:29,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[SYMPTOM],[SYMPTOM],Thrombosis,[SYMPTOM],62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568560,7/12/2014 14:29:24,,1321386085,7/12/2014 14:27:32,gifthulk,1,21916793,GBR,,,87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the HOPKINS LUPUS COHORT PERSPECTIVE,N/A,62,28,94,56,-1,RO-has_manifestation,906077-FS1,2]  Petri M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the HOPKINS LUPUS COHORT PERSPECTIVE [Editorial.,HOPKINS LUPUS COHORT PERSPECTIVE,SYSTEMIC LUPUS ERYTHEMATOSUS
502568561,7/12/2014 08:07:21,,1321262813,7/12/2014 08:06:40,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[PREVENTS],[PREVENTS],disseminated,na,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 08:15:24,,1321264958,7/12/2014 08:15:10,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,na,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 10:07:59,,1321302316,7/12/2014 10:06:57,vivatic,1,25451531,GBR,,,83.67.28.193,[OTHER],[OTHER],and,N/A,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 10:08:09,,1321302373,7/12/2014 10:07:31,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],evidence of and,NONE,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 10:15:23,,1321304563,7/12/2014 10:15:08,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 10:20:56,,1321306333,7/12/2014 10:20:17,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA,n/a,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 10:47:11,,1321314679,7/12/2014 10:46:15,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,They are not relate at all.,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 10:47:12,,1321314680,7/12/2014 10:46:23,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The diagnosis,N/A,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 11:11:34,,1321323129,7/12/2014 11:10:57,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[PART_OF],[PART_OF],rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA,N/A,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 13:25:16,,1321365714,7/12/2014 13:25:08,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],evidence,N/A,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 13:26:04,,1321366008,7/12/2014 13:25:42,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 13:42:06,,1321371388,7/12/2014 13:41:32,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 13:48:06,,1321373640,7/12/2014 13:47:29,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA,n/a,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 14:04:23,,1321378644,7/12/2014 14:03:39,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the absence of disseminated,na,118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568561,7/12/2014 14:27:27,,1321385503,7/12/2014 14:26:30,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],causes of thrombotic microangiopathy.,[CAUSES],118,80,134,113,-1,RO-has_manifestation,906432-FS1,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and THROMBOCYTOPENIA in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502568562,7/12/2014 07:27:41,,1321250399,7/12/2014 07:27:24,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],located in BONE,N/A,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 07:59:59,,1321260523,7/12/2014 07:59:01,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[LOCATION],[LOCATION],infection located in,na,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 08:01:02,,1321260930,7/12/2014 08:00:52,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BONE,da,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 09:09:18,,1321282787,7/12/2014 09:08:50,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[LOCATION],[LOCATION],an infection located in,n/a,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 10:01:44,,1321300309,7/12/2014 10:01:05,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[LOCATION],[LOCATION],an infection located in,N/A,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 10:09:51,,1321302927,7/12/2014 10:08:11,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],used,NONE,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 10:24:51,,1321307801,7/12/2014 10:24:36,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[LOCATION],[LOCATION],located,N/A,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 11:00:04,,1321318766,7/12/2014 10:59:24,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],located in,N/A,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 11:47:15,,1321334578,7/12/2014 11:45:46,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [SIDE_EFFECT],"[SYMPTOM]
[SIDE_EFFECT]",an infection located in,n/a,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 12:37:24,,1321349229,7/12/2014 12:36:37,neodev,1,18517457,GBR,,,86.29.147.112,[LOCATION],[LOCATION],an infection located in,N/a,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 13:42:18,,1321371509,7/12/2014 13:42:07,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[LOCATION],[LOCATION],located,N/A,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 13:42:17,,1321371527,7/12/2014 13:41:52,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],infection located in BONE,n/a,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 13:45:54,,1321372884,7/12/2014 13:45:34,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],infection located in,n/a,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 13:59:36,,1321377263,7/12/2014 13:59:06,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],infection located in,na,181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568562,7/12/2014 14:22:00,,1321383766,7/12/2014 14:21:28,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[LOCATION],[LOCATION],located in,[LOCATION],181,143,185,156,1,RO-disease_has_primary_anatomic_site,902077-FS1,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS
502568563,7/12/2014 07:27:59,,1321250514,7/12/2014 07:27:42,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],Treatment of,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 07:41:37,,1321254482,7/12/2014 07:41:16,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],Treatment of,na,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 07:56:46,,1321259433,7/12/2014 07:55:37,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.,da,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 08:12:37,,1321264294,7/12/2014 08:11:57,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Treatment TINEA PEDIS SULCONAZOLE NITRATE 1% CREAM,treats,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 08:19:03,,1321266050,7/12/2014 08:18:47,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],Treatment,na,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 09:23:52,,1321287411,7/12/2014 09:23:40,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[TREATS],[TREATS],Treatment,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 10:04:09,,1321301095,7/12/2014 10:03:08,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[TREATS],[TREATS],Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 10:08:35,,1321302496,7/12/2014 10:08:25,instagc,1,27753923,GBR,,,92.40.74.118,[CONTRAINDICATES],[CONTRAINDICATES],PEDIS with,n/a,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 10:11:49,,1321303489,7/12/2014 10:11:25,vivatic,1,25451531,GBR,,,83.67.28.193,[TREATS],[TREATS],Treatment of,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 10:23:59,,1321307536,7/12/2014 10:23:41,neodev,1,18517457,GBR,,,86.29.147.112,[TREATS],[TREATS],Treatment of TINEA PEDIS with,N/a,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 10:57:39,,1321317937,7/12/2014 10:56:50,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[TREATS],[TREATS],with,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 11:21:42,,1321327005,7/12/2014 11:20:49,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 13:24:04,,1321365343,7/12/2014 13:23:51,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],Treatment,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 13:25:11,,1321365682,7/12/2014 13:24:57,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Treatment with,n/a,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568563,7/12/2014 13:47:21,,1321373309,7/12/2014 13:47:06,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[TREATS],[TREATS],Treatment,N/A,36,53,47,81,1,RO-may_treat,907886-FS1,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
502568564,7/12/2014 07:21:13,,1321247850,7/12/2014 07:20:44,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],ATOPIC ATOPIC,N/A,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 08:01:34,,1321261089,7/12/2014 08:00:01,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[IS_A],[IS_A],ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs,na,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 08:01:46,,1321261126,7/12/2014 08:01:39,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],allergen.,da,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 08:31:31,,1321270634,7/12/2014 08:31:09,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],approximately 10%,n/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 08:51:45,,1321276805,7/12/2014 08:51:09,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],to cause as,N/A,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 09:06:56,,1321281871,7/12/2014 09:06:17,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[CAUSES],[CAUSES],cause canine,n/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 09:17:05,,1321285043,7/12/2014 09:15:58,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],ATOPIC,N/A,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 10:06:19,,1321301790,7/12/2014 10:04:18,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,none,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 10:10:17,,1321303021,7/12/2014 10:10:08,instagc,1,27753923,GBR,,,92.40.74.118,[MANIFESTATION],[MANIFESTATION],Japanese ATOPIC DERMATITIS,n/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 10:16:51,,1321305042,7/12/2014 10:15:54,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DERMATITIS ATOPIC,n/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 10:26:11,,1321308179,7/12/2014 10:25:31,neodev,1,18517457,GBR,,,86.29.147.112,[SYMPTOM],[SYMPTOM],is known to cause,N/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 10:48:09,,1321314953,7/12/2014 10:47:12,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Not related,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 11:33:59,,1321330550,7/12/2014 11:32:55,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION] [ASSOCIATED_WITH] [SIDE_EFFECT],"[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",cause approximately,n/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 13:13:27,,1321361926,7/12/2014 13:13:06,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC,n/a,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568564,7/12/2014 13:24:38,,1321365543,7/12/2014 13:24:30,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],cause,N/A,77,77,94,83,-1,RO-cause_of,900177-FS1,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
502568565,7/12/2014 07:27:23,,1321250299,7/12/2014 07:26:41,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],Adherence to can lead to the correction,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 07:59:42,,1321260437,7/12/2014 07:59:34,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],GLUTEN DIET,da,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 08:17:58,,1321265678,7/12/2014 08:17:33,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PREVENTS],[PREVENTS],"replacement iron stores, prevent recurrence",na,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 08:56:38,,1321278374,7/12/2014 08:55:36,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],prevent,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 09:20:02,,1321285926,7/12/2014 09:19:41,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],Adherence to a,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 09:29:44,,1321289357,7/12/2014 09:28:05,neodev,1,20929875,USA,MA,Boston,71.174.188.90,[PREVENTS],[PREVENTS],Adherence to GLUTEN FREE DIET can lead to correction of iron deficiency anemia,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 10:10:07,,1321302971,7/12/2014 10:09:59,instagc,1,27753923,GBR,,,92.40.74.118,[SYMPTOM],[SYMPTOM],CELIAC DISEASE,n/a,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 10:20:32,,1321306171,7/12/2014 10:19:57,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[PREVENTS],[PREVENTS],prevent,n/a,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 10:22:45,,1321307043,7/12/2014 10:21:48,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],GLUTEN FREE DIET CELIAC DISEASE,n/a,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 10:44:41,,1321313931,7/12/2014 10:43:48,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],patients with can lead to correction,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 12:08:46,,1321341294,7/12/2014 12:07:54,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],can prevent,n/a,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 12:37:43,,1321349334,7/12/2014 12:37:25,neodev,1,18517457,GBR,,,86.29.147.112,[TREATS],[TREATS],in patients with,N/a,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 12:46:31,,1321352320,7/12/2014 12:46:08,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Adherence to a,n/a,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 13:24:29,,1321365482,7/12/2014 13:24:14,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],lead,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568565,7/12/2014 13:43:08,,1321371846,7/12/2014 13:42:55,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,17,51,33,65,-1,RO-has_causative_agent,903642-FS1,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
502568566,7/12/2014 08:00:51,,1321260873,7/12/2014 08:00:44,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],patients,da,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 08:07:56,,1321262970,7/12/2014 08:07:22,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"MIGRAINE HEADACHES NASOSINUS headaches, or",na,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 08:59:47,,1321279439,7/12/2014 08:59:22,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A],[IS_A],or,n/a,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 09:15:28,,1321284518,7/12/2014 09:15:11,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],or,N/A,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 09:57:43,,1321298941,7/12/2014 09:56:28,vivatic,1,25451531,GBR,,,83.67.28.193,[OTHER],[OTHER],or,N/A,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 10:01:03,,1321300088,7/12/2014 09:59:43,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"patients in these studies have headaches, or",N/A,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 10:13:10,,1321303863,7/12/2014 10:13:02,instagc,1,27753923,GBR,,,92.40.74.118,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TENSION HEADACHES,n/a,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 10:24:10,,1321307589,7/12/2014 10:23:39,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[NONE],[NONE],n/a,Are two different types of h eadaches.,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 10:24:46,,1321307772,7/12/2014 10:24:05,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM],[SYMPTOM],or,none,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 10:45:22,,1321314142,7/12/2014 10:44:42,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"have headaches, or",N/A,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 10:59:11,,1321318451,7/12/2014 10:57:40,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[NONE],[NONE],N/A,"They are talking about two separate issues, as signified by the use of ""or"".",39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 11:59:58,,1321338858,7/12/2014 11:58:25,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[NONE],[NONE],its asking a question,its asking a question about if either have been suffered by someone. it makes no other statement of fact.,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 13:28:07,,1321366783,7/12/2014 13:27:49,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or HEADACHES,n/a,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 13:40:05,,1321370783,7/12/2014 13:38:24,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[NONE],[NONE],OR,statement is a question. one or the other. no relationship,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568566,7/12/2014 13:45:33,,1321372786,7/12/2014 13:44:30,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,it's either/or,39,100,85,117,-1,RO-has_definitional_manifestation,904855-FS1,"Did the patients in these studies have TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS headaches, or CLUSTER HEADACHES",TENSION HEADACHES MIGRAINE HEADACHES NASOSINUS,CLUSTER HEADACHES
502568567,7/12/2014 07:58:17,,1321259877,7/12/2014 07:57:38,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[SYMPTOM],[SYMPTOM],major symptoms are,na,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 08:14:38,,1321264794,7/12/2014 08:13:42,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],The major symptoms the same classic RENAL CELL CARCINOMA: HAEMATURIA,symptom,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 08:18:14,,1321265815,7/12/2014 08:17:59,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[SYMPTOM],[SYMPTOM],symptoms,na,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 08:29:15,,1321269858,7/12/2014 08:28:09,neodev,1,11598752,CAN,ON,Toronto,216.165.208.242,[SYMPTOM],[SYMPTOM],symptoms,THERE ARE MORE THAN 1 CAUSE,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 08:29:34,,1321269969,7/12/2014 08:29:08,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RENAL CELL CARCINOMA: HAEMATURIA,n/a,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 08:55:33,,1321277998,7/12/2014 08:55:08,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],major symptoms,n/a,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 09:11:18,,1321283375,7/12/2014 09:10:31,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A],[IS_A],same as,n/a,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 09:22:50,,1321286974,7/12/2014 09:22:30,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],major symptoms,N/A,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 10:01:30,,1321300229,7/12/2014 10:01:00,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RENAL CELL CARCINOMA: HAEMATURIA,n/a,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 10:12:50,,1321303765,7/12/2014 10:12:40,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],RENAL CELL CARCINOMA:,n/a,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 10:13:25,,1321303946,7/12/2014 10:12:48,vivatic,1,25451531,GBR,,,83.67.28.193,[SYMPTOM],[SYMPTOM],major symptoms,N/A,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 10:18:43,,1321305588,7/12/2014 10:18:01,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[SYMPTOM],[SYMPTOM],major symptoms are the same,n/a,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 10:26:07,,1321308170,7/12/2014 10:25:15,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],classic,none,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 10:59:21,,1321318514,7/12/2014 10:58:29,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],same as,N/A,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568567,7/12/2014 11:08:48,,1321322214,7/12/2014 11:08:03,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[SYMPTOM],[SYMPTOM],RENAL CELL CARCINOMA: HAEMATURIA,N/A,72,50,82,70,1,RO-disease_may_have_finding,902711-FS1,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
502568568,7/12/2014 07:57:16,,1321259584,7/12/2014 07:57:06,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],PULMONARY SYNDROME,da,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 08:41:32,,1321273602,7/12/2014 08:41:06,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",viral infection,n/a,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 08:50:19,,1321276366,7/12/2014 08:49:43,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 08:59:21,,1321279252,7/12/2014 08:57:58,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],infection from,n/a,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 09:18:00,,1321285313,7/12/2014 09:17:39,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],from a new strain of,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 09:52:33,,1321296988,7/12/2014 09:51:46,vivatic,1,25451531,GBR,,,83.67.28.193,[CAUSES],[CAUSES],viral infection from a new strain of,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:12:15,,1321303612,7/12/2014 10:12:07,instagc,1,27753923,GBR,,,92.40.74.118,[PART_OF],[PART_OF],HANTAVIRUS PULMONARY,n/a,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:12:50,,1321303781,7/12/2014 10:12:10,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],HANTAVIRUS PULMONARY SYNDROME (HPS) HANTAVIRUS,n/a,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:14:48,,1321304424,7/12/2014 10:14:29,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],from a new strain,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:19:33,,1321305876,7/12/2014 10:18:52,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is,none,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:53:02,,1321316515,7/12/2014 10:52:19,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],HANTAVIRUS PULMONARY SYNDROME a new strain of HANTAVIRUS,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:56:26,,1321317576,7/12/2014 10:55:38,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[MANIFESTATION],[MANIFESTATION],from a new strain,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 10:59:58,,1321318745,7/12/2014 10:59:13,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[CAUSES],[CAUSES],new strain of,N/A,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 11:45:46,,1321334089,7/12/2014 11:44:06,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[IS_A] [MANIFESTATION],"[MANIFESTATION]
[IS_A]",is a viral infection,n/a,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568568,7/12/2014 12:46:47,,1321352402,7/12/2014 12:46:31,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],viral infection from,n/a,0,0,10,29,1,RO-has_causative_agent,903801-FS1,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
502568569,7/12/2014 07:13:33,,1321245454,7/12/2014 07:13:04,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],to,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 07:56:29,,1321259336,7/12/2014 07:55:21,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests,na,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 07:59:33,,1321260357,7/12/2014 07:59:24,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PART_OF],[PART_OF],allergy determined,da,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 08:20:10,,1321266453,7/12/2014 08:19:56,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],duration severity presence,na,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 09:00:52,,1321279756,7/12/2014 09:00:32,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to,n/a,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 10:05:50,,1321301635,7/12/2014 10:04:43,vivatic,1,25451531,GBR,,,83.67.28.193,[CONTRAINDICATES],[CONTRAINDICATES],HYPERREACTIVITY to,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 10:17:59,,1321305355,7/12/2014 10:17:08,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],to,none,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 10:22:56,,1321307085,7/12/2014 10:22:36,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[CAUSES],[CAUSES],to,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 10:54:39,,1321317045,7/12/2014 10:53:55,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 11:15:12,,1321324522,7/12/2014 11:14:05,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[MANIFESTATION],[MANIFESTATION],BRONCHIAL HYPERREACTIVITY to METHACHOLINE,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 11:39:01,,1321331949,7/12/2014 11:37:48,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],determined inhalation,n/a,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 13:28:03,,1321366748,7/12/2014 13:27:52,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],and,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 13:42:44,,1321371687,7/12/2014 13:42:18,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],to,n/a,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 13:44:29,,1321372393,7/12/2014 13:43:57,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation,n/a,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568569,7/12/2014 13:47:59,,1321373597,7/12/2014 13:47:45,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[TREATS],[TREATS],tests,N/A,90,119,115,131,1,RO-may_diagnose,906914-FS1,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502568570,7/12/2014 07:58:19,,1321259903,7/12/2014 07:58:09,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],THROMBOCYTOSES,da,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 08:09:17,,1321263382,7/12/2014 08:08:41,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],is one of the forms,na,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 08:30:26,,1321270230,7/12/2014 08:28:48,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one of the forms,N/A,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 09:04:18,,1321281098,7/12/2014 09:04:01,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],one of the forms,n/a,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 09:11:12,,1321283350,7/12/2014 09:10:51,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],is one of the forms of,N/A,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 10:20:56,,1321306317,7/12/2014 10:20:38,neodev,1,18517457,GBR,,,86.29.147.112,[MANIFESTATION],[MANIFESTATION],is one of the forms of,N/a,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 10:24:03,,1321307542,7/12/2014 10:23:11,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],is,none,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 11:09:48,,1321322517,7/12/2014 11:08:50,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[CAUSES],[CAUSES],one of the forms of,N/A,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 11:16:47,,1321325129,7/12/2014 11:16:19,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],(ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,N/A,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 13:28:26,,1321366888,7/12/2014 13:28:18,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],PRIMARY,N/A,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 13:40:26,,1321370861,7/12/2014 13:40:07,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[IS_A],[IS_A],is one,n/a,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 13:42:01,,1321371355,7/12/2014 13:40:08,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],is one of the forms of,n/a,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 13:46:53,,1321373217,7/12/2014 13:46:29,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[IS_A],[IS_A],is one of the forms,N/A,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 14:05:39,,1321378986,7/12/2014 14:04:25,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],forms,na,64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568570,7/12/2014 14:20:25,,1321383284,7/12/2014 14:19:43,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [PART_OF],"[CAUSES]
[PART_OF]",one of the forms,[CAUSES] [PART_OF],64,8,95,40,1,RO-disease_has_finding,901949-FS1,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
502568571,7/12/2014 07:40:36,,1321254267,7/12/2014 07:39:56,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing can preclude,na,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 07:57:37,,1321259680,7/12/2014 07:57:29,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],necessity for,da,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 08:10:30,,1321263728,7/12/2014 08:10:08,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"diagnostic studies,",na,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 08:35:08,,1321271731,7/12/2014 08:34:03,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 08:43:35,,1321274113,7/12/2014 08:41:59,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],use of diagnostic,N/A,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 09:15:57,,1321284675,7/12/2014 09:15:29,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,N/A,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 09:25:22,,1321287837,7/12/2014 09:25:09,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[TREATS],[TREATS],correct use,N/A,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 10:05:08,,1321301400,7/12/2014 10:04:27,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PHARMACOLOGIC MYDRIASIS TOPICAL PILOCARPINE,n/a,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 10:09:05,,1321302678,7/12/2014 10:08:47,instagc,1,27753923,GBR,,,92.40.74.118,[CAUSES],[CAUSES],invasive diagnostic,n/a,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 10:21:27,,1321306579,7/12/2014 10:20:57,neodev,1,18517457,GBR,,,86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and correct use of,N/a,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 10:47:59,,1321314878,7/12/2014 10:47:18,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],correct use of,N/A,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 11:11:19,,1321323022,7/12/2014 11:10:31,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Can't see the relation between the two.,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 12:05:27,,1321340590,7/12/2014 12:04:52,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correct use of,n/a,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 13:24:36,,1321365533,7/12/2014 13:24:15,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],correct use of,n/a,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568571,7/12/2014 13:27:20,,1321366464,7/12/2014 13:27:07,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],PHARMACOLOGIC,N/A,75,118,98,137,1,RO-may_treat,908182-FS1,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
502568572,7/12/2014 07:20:44,,1321247686,7/12/2014 07:20:24,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 08:10:53,,1321263846,7/12/2014 08:10:30,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],represent,na,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 08:54:13,,1321277571,7/12/2014 08:53:45,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 09:08:15,,1321282368,7/12/2014 09:07:57,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 09:08:16,,1321282369,7/12/2014 09:07:56,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 10:24:52,,1321307798,7/12/2014 10:24:21,neodev,1,18517457,GBR,,,86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/a,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 10:49:25,,1321315399,7/12/2014 10:48:46,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 11:03:01,,1321319854,7/12/2014 11:02:22,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 11:17:51,,1321325581,7/12/2014 11:16:48,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) anomalies associated with SEIZURES,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 13:25:07,,1321365674,7/12/2014 13:24:58,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],anomalies,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 13:40:07,,1321370802,7/12/2014 13:39:39,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],vascular anomalies associated with,n/a,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 13:40:43,,1321370949,7/12/2014 13:40:28,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 13:48:13,,1321373653,7/12/2014 13:48:00,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 14:03:37,,1321378393,7/12/2014 14:02:56,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with SEIZURES,na,83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568572,7/12/2014 14:23:23,,1321384189,7/12/2014 14:22:52,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],83,0,91,32,1,RO-has_manifestation,906281-FS1,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs) are CNS vascular anomalies associated with SEIZURES headaches and hemorrhagic strokes and represent 10 20% of cerebral lesions.,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS
502568573,7/12/2014 07:19:28,,1321247303,7/12/2014 07:18:53,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],or,N/A,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 07:57:37,,1321259679,7/12/2014 07:56:30,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or LUPUS,na,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 08:38:46,,1321272744,7/12/2014 08:38:26,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 08:56:31,,1321278348,7/12/2014 08:55:55,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],or,n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 09:03:39,,1321280874,7/12/2014 09:02:51,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],or,n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 09:09:15,,1321282761,7/12/2014 09:08:18,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 10:09:13,,1321302705,7/12/2014 10:08:23,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIPHOSPHOLIPID ANTIBODIES LUPUS,n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 10:20:37,,1321306197,7/12/2014 10:19:35,neodev,1,18517457,GBR,,,86.29.147.112,[OTHER],[OTHER],or,N/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 10:53:53,,1321316776,7/12/2014 10:53:04,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],"ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant,",N/A,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 11:02:19,,1321319630,7/12/2014 11:01:27,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],"or LUPUS anticoagulant,",N/A,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 11:35:10,,1321330892,7/12/2014 11:34:00,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[IS_A] [ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]",Modified,n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 13:27:50,,1321366648,7/12/2014 13:27:42,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],(mm3),N/A,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 13:43:20,,1321371933,7/12/2014 13:42:45,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],IgG cardiolipin or,n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 13:45:31,,1321372756,7/12/2014 13:45:20,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568573,7/12/2014 13:49:43,,1321374118,7/12/2014 13:49:13,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],"(anti cardiolipin or LUPUS anticoagulant,",n/a,324,384,351,389,-1,RO-has_manifestation,906360-FS1,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti dsDNA or Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES (anti IgM or IgG cardiolipin or LUPUS anticoagulant, or false positive test for syphilis) Antinuclear antibody  Anti RNP Anti Ro/SSA Anti La/SSB Other antibodies Modified from tvml 29tvml.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS
502568574,7/12/2014 07:16:39,,1321246399,7/12/2014 07:16:03,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was assessed with,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 08:05:41,,1321262315,7/12/2014 08:05:13,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed,na,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 08:15:41,,1321265030,7/12/2014 08:15:25,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],was assessed,na,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 08:30:47,,1321270363,7/12/2014 08:30:22,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was assessed with,n/a,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 08:35:45,,1321271913,7/12/2014 08:35:10,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],assessed with,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 09:14:40,,1321284238,7/12/2014 09:14:23,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed with,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 10:23:46,,1321307434,7/12/2014 10:23:32,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed with,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 11:16:17,,1321324891,7/12/2014 11:15:22,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],ANTIANGINAL EFFICACY was assessed with ANGINA DIARES,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 11:56:20,,1321337718,7/12/2014 11:55:47,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",assessed with,n/a,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 12:35:34,,1321348678,7/12/2014 12:35:14,neodev,1,18517457,GBR,,,86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed with,N/a,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 13:25:55,,1321365971,7/12/2014 13:25:48,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],patients,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 13:36:39,,1321369726,7/12/2014 13:36:16,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed,n/a,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 13:44:37,,1321372463,7/12/2014 13:44:23,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was assessed with,N/A,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 13:47:28,,1321373399,7/12/2014 13:47:02,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],"was assessed with ANGINA DIARES investigators,",n/a,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568574,7/12/2014 14:09:06,,1321380047,7/12/2014 14:06:43,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],assessed with,na,39,0,52,20,1,RO-may_prevent,907376-FS1,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY
502568575,7/12/2014 07:59:00,,1321260150,7/12/2014 07:58:18,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[LOCATION],[LOCATION],disease of,na,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 08:00:35,,1321260763,7/12/2014 08:00:28,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],INFLAMMATORY,da,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 09:10:04,,1321282988,7/12/2014 09:09:45,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],represents,n/a,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 09:20:26,,1321286040,7/12/2014 09:20:03,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],represents different phenotypes of,N/A,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 09:48:19,,1321295514,7/12/2014 09:47:12,vivatic,1,25451531,GBR,,,83.67.28.193,[LOCATION],[LOCATION],of,N/A,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 10:15:42,,1321304686,7/12/2014 10:15:24,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],represents different,N/A,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 10:17:33,,1321305187,7/12/2014 10:16:56,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",INFLAMMATORY BOWEL DISEASE (IBD) GASTROINTESTINAL TRACT,n/a,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 10:29:47,,1321309476,7/12/2014 10:29:28,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],represents,none,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 10:48:44,,1321315204,7/12/2014 10:48:01,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],represents different phenotypes,N/A,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 11:12:46,,1321323533,7/12/2014 11:11:35,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[SYMPTOM],[SYMPTOM],represents different phenotypes of,N/A,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 11:56:53,,1321337882,7/12/2014 11:56:22,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],represents different inflammatory disease of,n/a,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 12:33:38,,1321348050,7/12/2014 12:33:04,neodev,1,18517457,GBR,,,86.29.147.112,[LOCATION],[LOCATION],disease of,N/a,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 13:15:16,,1321362498,7/12/2014 13:14:36,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],of,n/a,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 13:26:58,,1321366341,7/12/2014 13:26:48,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],different,N/A,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568575,7/12/2014 13:43:53,,1321372112,7/12/2014 13:43:21,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[IS_A],[IS_A],represents different,n/a,124,9,146,35,1,RO-has_finding_site,905078-FS1,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE
502568576,7/12/2014 07:10:35,,1321244558,7/12/2014 07:10:07,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],OVERDOSE DRUGS,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 08:40:14,,1321273231,7/12/2014 08:39:56,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[SIDE_EFFECT],[SIDE_EFFECT],after both,n/a,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 08:41:58,,1321273713,7/12/2014 08:41:17,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 09:04:00,,1321281016,7/12/2014 09:03:40,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],or,n/a,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:09:57,,1321302954,7/12/2014 10:09:48,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],interval OVERDOSE DRUGS,n/a,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:12:04,,1321303562,7/12/2014 10:09:53,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,NONE,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:12:47,,1321303775,7/12/2014 10:11:50,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],or other,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:13:54,,1321304121,7/12/2014 10:13:34,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:15:49,,1321304724,7/12/2014 10:15:07,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SIDE_EFFECT],[SIDE_EFFECT],OVERDOSE DRUGS,n/a,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:23:38,,1321307354,7/12/2014 10:22:34,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[NONE],[NONE],n/a,"Both words have relations with the sentence before, not with each other",273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:49:25,,1321315407,7/12/2014 10:48:42,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 10:57:09,,1321317795,7/12/2014 10:56:28,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],other,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 11:07:33,,1321321773,7/12/2014 11:06:30,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[CAUSES],[CAUSES],coadministration of DRUGS,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 13:10:51,,1321361175,7/12/2014 13:09:48,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[CONTRAINDICATES],[CONTRAINDICATES],interfere,n/a,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568576,7/12/2014 13:26:05,,1321366011,7/12/2014 13:25:57,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],coadministration,N/A,273,209,278,217,1,RO-has_causative_agent,903891-FS1,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
502568577,7/12/2014 07:17:10,,1321246588,7/12/2014 07:16:40,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],in the treatment of,N/A,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 07:57:59,,1321259789,7/12/2014 07:57:51,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],Fontaine Chouinard,da,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 08:14:42,,1321264812,7/12/2014 08:14:23,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],open clinical trial treatment,na,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 08:41:54,,1321273700,7/12/2014 08:41:33,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",treatment of,n/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 08:59:46,,1321279422,7/12/2014 08:59:19,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment of,N/A,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 09:10:50,,1321283204,7/12/2014 09:10:33,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 09:13:04,,1321283828,7/12/2014 09:12:46,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 10:11:22,,1321303363,7/12/2014 10:10:41,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],FLUOXETINE OBSESSIVE COMPULSIVE DISORDER,n/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 10:19:24,,1321305799,7/12/2014 10:18:44,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[TREATS],[TREATS],treatment,n/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 10:23:14,,1321307238,7/12/2014 10:22:57,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[TREATS],[TREATS],the treatment of,N/A,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 10:25:29,,1321308006,7/12/2014 10:25:12,neodev,1,18517457,GBR,,,86.29.147.112,[TREATS],[TREATS],in the treatment of,N/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 11:18:30,,1321325879,7/12/2014 11:18:14,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[TREATS],[TREATS],in the treatment of,N/A,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 11:22:47,,1321327301,7/12/2014 11:21:43,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],in the treatment of,N/A,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 11:50:37,,1321335681,7/12/2014 11:49:17,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],treatment,n/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568577,7/12/2014 13:37:45,,1321370000,7/12/2014 13:37:28,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],treatment of,n/a,82,51,111,61,1,RO-may_treat,907730-FS1,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE
502568578,7/12/2014 07:50:04,,1321257035,7/12/2014 07:48:58,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],migraine during headache,na,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 08:10:06,,1321263602,7/12/2014 08:09:39,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],"saliva with migraine during headache headache periods,",na,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 08:28:47,,1321269736,7/12/2014 08:27:30,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],type,N/A,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 08:41:05,,1321273488,7/12/2014 08:40:42,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",MIGRAINE HEADACHE,n/a,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 09:13:16,,1321283872,7/12/2014 09:11:55,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],in the patients with,N/A,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 09:25:08,,1321287755,7/12/2014 09:24:41,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],"migraine during headache attacks,",N/A,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 10:07:50,,1321302253,7/12/2014 10:07:35,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],18.3 pmol/mL,n/a,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 10:09:02,,1321302662,7/12/2014 10:08:01,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],tension type,N/A,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 10:09:52,,1321302926,7/12/2014 10:09:18,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",MIGRAINE HEADACHE,n/a,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 10:18:11,,1321305453,7/12/2014 10:17:21,neodev,1,18517457,GBR,,,86.29.147.112,[MANIFESTATION],[MANIFESTATION],"patients with migraine during headache attacks,",N/a,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 10:51:06,,1321315842,7/12/2014 10:50:21,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],patients with tension type,N/A,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 10:53:24,,1321316634,7/12/2014 10:51:34,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[NONE],[NONE],N/A,They are talking about the saliva acid levels of two different types of headaches and they are not linked.,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 11:10:02,,1321322570,7/12/2014 11:09:02,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Migraine's and Headaches are two separate things.,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 12:07:52,,1321341088,7/12/2014 12:06:43,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES] [SYMPTOM] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]","migraine during headache attacks,",n/a,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568578,7/12/2014 13:14:35,,1321362269,7/12/2014 13:14:11,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with migraine during headache,n/a,254,166,262,174,-1,RO-has_definitional_manifestation,904663-FS1,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
502568579,7/12/2014 07:26:17,,1321249869,7/12/2014 07:25:35,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],Pathogenesis management of pain in OSTEOARTHRITIS,N/A,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 07:57:50,,1321259717,7/12/2014 07:57:38,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],in patients,da,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 08:02:29,,1321261354,7/12/2014 08:01:36,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],management of pain,na,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 08:11:04,,1321263879,7/12/2014 08:09:40,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],NAPROXEN management of pain OSTEOARTHRITIS,treats,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 08:16:26,,1321265281,7/12/2014 08:15:58,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],Comparison,na,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 08:37:01,,1321272232,7/12/2014 08:36:25,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment of,N/A,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 08:37:28,,1321272387,7/12/2014 08:36:46,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",with NAPROXEN and ibuprofen OSTEOARTHRITIS,n/a,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 09:04:55,,1321281268,7/12/2014 09:02:40,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 09:05:31,,1321281466,7/12/2014 09:04:48,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[TREATS],[TREATS],treatment of,n/a,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 09:54:28,,1321297686,7/12/2014 09:53:17,vivatic,1,25451531,GBR,,,83.67.28.193,[TREATS],[TREATS],randomised controlled trial,N/A,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 10:11:01,,1321303258,7/12/2014 10:10:51,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],knee Lancet,n/a,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 10:18:45,,1321305594,7/12/2014 10:18:12,neodev,1,18517457,GBR,,,86.29.147.112,[TREATS],[TREATS],management of pain in,N/a,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 10:22:36,,1321307021,7/12/2014 10:22:08,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[TREATS],[TREATS],management of pain,N/A,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 10:27:20,,1321308557,7/12/2014 10:26:39,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],in,none,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568579,7/12/2014 10:52:38,,1321316399,7/12/2014 10:51:55,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],controlled management of pain,N/A,450,253,464,261,1,RO-may_treat,907732-FS1,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN
502568580,7/12/2014 07:23:11,,1321248740,7/12/2014 07:22:59,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with a history of TRAUMA,N/A,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 08:11:55,,1321264106,7/12/2014 08:11:05,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",PURTSCHER'S RETINOPATHY patients history TRAUMA,manifestation; associated with,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 08:43:47,,1321274184,7/12/2014 08:43:26,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",history of,n/a,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 08:53:44,,1321277450,7/12/2014 08:53:02,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 08:54:01,,1321277515,7/12/2014 08:53:05,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],seen,n/a,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 09:23:08,,1321287083,7/12/2014 09:22:43,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[SYMPTOM],[SYMPTOM],seen in patients,N/A,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 10:10:35,,1321303101,7/12/2014 10:09:56,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PURTSCHER'S RETINOPATHY TRAUMA,n/a,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 10:11:47,,1321303488,7/12/2014 10:11:30,instagc,1,27753923,GBR,,,92.40.74.118,[SIDE_EFFECT],[SIDE_EFFECT],PURTSCHER'S RETINOPATHY,n/a,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 10:19:10,,1321305742,7/12/2014 10:18:46,neodev,1,18517457,GBR,,,86.29.147.112,[SYMPTOM],[SYMPTOM],seen in patients with,Na,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 11:17:03,,1321325224,7/12/2014 11:16:42,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seen in patients with TRAUMA,N/A,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 13:23:40,,1321365232,7/12/2014 13:23:31,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],patients,N/A,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 13:26:38,,1321366235,7/12/2014 13:26:05,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],patients with a history of,n/a,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 13:42:54,,1321371722,7/12/2014 13:42:38,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seen in with a history,N/A,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 13:42:56,,1321371725,7/12/2014 13:42:02,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],"is a rare condition, seen in patients with a history",n/a,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568580,7/12/2014 14:06:41,,1321379312,7/12/2014 14:05:41,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",seen in,na,0,80,23,86,1,RO-cause_of,900463-FS1,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
502568581,7/12/2014 07:10:07,,1321244314,7/12/2014 07:09:53,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],(principally,N/A,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 07:59:22,,1321260285,7/12/2014 07:59:14,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],Warnings/Precautions 134,da,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 08:11:43,,1321264042,7/12/2014 08:11:17,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[SIDE_EFFECT],[SIDE_EFFECT],potentially fatal,na,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 08:12:19,,1321264231,7/12/2014 08:11:39,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[IS_A],[IS_A],LEUKOPENIA (principally GRANULOCYTOPENIA);,na,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 08:42:58,,1321273965,7/12/2014 08:42:40,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKOPENIA GRANULOCYTOPENIA);,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 09:01:21,,1321279993,7/12/2014 09:00:54,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A],[IS_A],(principally,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 10:06:51,,1321302015,7/12/2014 10:06:12,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKOPENIA GRANULOCYTOPENIA);,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 10:11:10,,1321303303,7/12/2014 10:11:03,instagc,1,27753923,GBR,,,92.40.74.118,[CAUSES],[CAUSES],Warnings/Precautions Myelosuppression,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 10:28:21,,1321308873,7/12/2014 10:27:53,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],by,none,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 11:17:30,,1321325415,7/12/2014 11:17:04,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[IS_A],[IS_A],LEUKOPENIA (principally GRANULOCYTOPENIA);,N/A,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 11:37:47,,1321331609,7/12/2014 11:37:01,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],manifested commonly by,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 13:11:00,,1321361229,7/12/2014 13:10:37,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],(principally,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 13:27:41,,1321366607,7/12/2014 13:27:32,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],LEUKOPENIA,N/A,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 13:43:20,,1321371934,7/12/2014 13:43:09,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(principally,N/A,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568581,7/12/2014 13:51:58,,1321374906,7/12/2014 13:51:39,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],(principally,n/a,272,296,282,312,-1,RO-has_definitional_manifestation,904665-FS1,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by LEUKOPENIA (principally GRANULOCYTOPENIA);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",LEUKOPENIA,GRANULOCYTOPENIA
502568582,7/12/2014 07:09:51,,1321244233,7/12/2014 07:08:55,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],including,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 08:00:27,,1321260715,7/12/2014 08:00:17,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],reviewed.,da,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 08:19:44,,1321266319,7/12/2014 08:18:19,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WORK RELATED ALLERGY including immediate DELAYED TYPE HYPERSENSITIVITIES,associated with,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 08:43:25,,1321274093,7/12/2014 08:43:00,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",WORK RELATED ALLERGY DELAYED TYPE HYPERSENSITIVITIES,n/a,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 09:06:45,,1321281789,7/12/2014 09:06:09,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],including,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 09:08:49,,1321282579,7/12/2014 09:08:17,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A],[IS_A],including immediate and,n/a,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 10:03:37,,1321300957,7/12/2014 10:03:09,vivatic,1,25451531,GBR,,,83.67.28.193,[PREVENTS],[PREVENTS],methods of protecting,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 10:09:26,,1321302789,7/12/2014 10:09:17,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],methods protecting worker,n/a,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 10:24:50,,1321307780,7/12/2014 10:24:11,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[SYMPTOM],[SYMPTOM],including,n/a,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 10:52:18,,1321316259,7/12/2014 10:50:58,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],WORK RELATED ALLERGY including DELAYED TYPE HYPERSENSITIVITIES,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 10:55:36,,1321317312,7/12/2014 10:54:58,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],including immediate,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 11:13:40,,1321323902,7/12/2014 11:12:47,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[IS_A],[IS_A],including,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 11:58:25,,1321338352,7/12/2014 11:56:55,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES] [MANIFESTATION] [ASSOCIATED_WITH],"[CAUSES]
[MANIFESTATION]
[ASSOCIATED_WITH]",protecting a worker from including immediate and,n/a,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 13:37:26,,1321369911,7/12/2014 13:36:36,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],including immediate and DELAYED TYPE HYPERSENSITIVITIES,n/a,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568582,7/12/2014 13:47:34,,1321373439,7/12/2014 13:47:22,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[IS_A],[IS_A],including,N/A,61,106,81,137,-1,RO-cause_of,900222-FS1,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
502568583,7/12/2014 07:24:11,,1321249081,7/12/2014 07:23:44,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compatible with,N/A,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 07:48:55,,1321256693,7/12/2014 07:47:50,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compatible with,na,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 08:34:03,,1321271412,7/12/2014 08:33:25,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],phenotypic compatible with,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 08:39:12,,1321272898,7/12/2014 08:37:02,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],identified by,N/A,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 09:10:29,,1321283123,7/12/2014 09:10:06,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compatible with,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 10:06:56,,1321302024,7/12/2014 10:05:51,vivatic,1,25451531,GBR,,,83.67.28.193,[MANIFESTATION],[MANIFESTATION],compatible with status,N/A,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 10:10:50,,1321303191,7/12/2014 10:10:41,instagc,1,27753923,GBR,,,92.40.74.118,[CONTRAINDICATES],[CONTRAINDICATES],LUNG CARCINOMAS,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 10:21:44,,1321306637,7/12/2014 10:21:05,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],LUNG CARCINOMAS (SCLC) NEUROENDOCRINE DIFFERENTIATION,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 10:22:31,,1321306976,7/12/2014 10:22:06,neodev,1,18517457,GBR,,,86.29.147.112,[MANIFESTATION],[MANIFESTATION],compatible with a status,N/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 10:41:18,,1321313053,7/12/2014 10:40:31,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],features compatible,N/A,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 10:56:49,,1321317649,7/12/2014 10:55:44,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compatible,N/A,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 11:20:20,,1321326554,7/12/2014 11:19:40,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],LUNG CARCINOMAS features compatible with a NEUROENDOCRINE DIFFERENTIATION status,N/A,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 11:49:16,,1321335268,7/12/2014 11:48:36,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",compatible identified by,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 13:06:28,,1321359713,7/12/2014 13:05:50,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compatible,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568583,7/12/2014 13:25:40,,1321365909,7/12/2014 13:25:12,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],status can be identified,n/a,89,28,119,50,-1,RO-disease_has_finding,901753-FS1,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC)
502568584,7/12/2014 07:59:51,,1321260499,7/12/2014 07:59:43,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],Pregnancy associated,da,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 08:15:27,,1321264963,7/12/2014 08:14:39,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [SIDE_EFFECT],"[MANIFESTATION]
[SIDE_EFFECT]",PREGNANCY COMPLICATIONS such as PREECLAMPSIA,manifestation or side effect,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 08:19:55,,1321266346,7/12/2014 08:19:40,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],associated increased,na,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 08:24:27,,1321267899,7/12/2014 08:23:50,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 08:32:35,,1321270994,7/12/2014 08:32:01,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",such as,n/a,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 09:15:09,,1321284417,7/12/2014 09:14:42,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],such as,N/A,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 09:53:16,,1321297295,7/12/2014 09:52:34,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],such as,N/A,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 10:10:30,,1321303089,7/12/2014 10:10:19,instagc,1,27753923,GBR,,,92.40.74.118,[CONTRAINDICATES],[CONTRAINDICATES],"oxidative stress,",n/a,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 10:20:12,,1321306108,7/12/2014 10:19:26,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PREGNANCY COMPLICATIONS PREECLAMPSIA,n/a,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 10:23:40,,1321307365,7/12/2014 10:23:20,neodev,1,18517457,GBR,,,86.29.147.112,[SYMPTOM],[SYMPTOM],such as PREECLAMPSIA,N/a,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 10:30:54,,1321309771,7/12/2014 10:30:24,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,none,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 10:58:27,,1321318137,7/12/2014 10:57:50,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],such as,N/A,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 11:36:08,,1321331253,7/12/2014 11:35:11,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated considered important,n/a,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 11:52:17,,1321336339,7/12/2014 11:51:11,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[IS_A],[IS_A],considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA,N/A,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568584,7/12/2014 13:08:53,,1321360533,7/12/2014 13:08:20,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],considered important,n/a,121,153,144,165,-1,RO-disease_has_finding,901876-FS1,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
502568585,7/12/2014 07:22:19,,1321248343,7/12/2014 07:21:50,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],ANGINA suggests that the PAIN,N/A,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 08:03:40,,1321261724,7/12/2014 08:02:30,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",ANGINA suggests that the PAIN,na,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 08:12:31,,1321264284,7/12/2014 08:12:14,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],does not rule out,na,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 08:16:41,,1321265330,7/12/2014 08:15:28,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],ANGINA suggests PAIN ischemic.,symptom,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 08:31:59,,1321270802,7/12/2014 08:31:33,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggests that the ischemic.,n/a,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 08:49:42,,1321276114,7/12/2014 08:48:06,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",ECG taken,N/A,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 09:09:43,,1321282893,7/12/2014 09:09:20,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggests,n/a,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 09:23:38,,1321287278,7/12/2014 09:23:09,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[SYMPTOM],[SYMPTOM],"taken during pain,",N/A,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 09:50:06,,1321296137,7/12/2014 09:48:20,vivatic,1,25451531,GBR,,,83.67.28.193,[MANIFESTATION],[MANIFESTATION],"taken during pain,",N/A,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 10:15:02,,1321304460,7/12/2014 10:14:23,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANGINA PAIN,n/a,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 10:22:10,,1321306863,7/12/2014 10:21:02,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],suggests,none,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 13:23:50,,1321365262,7/12/2014 13:23:42,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],unstable,N/A,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 13:27:02,,1321366378,7/12/2014 13:26:39,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],is not ischemic.,n/a,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 13:41:51,,1321371308,7/12/2014 13:41:19,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"taken during pain,",n/a,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568585,7/12/2014 13:43:56,,1321372138,7/12/2014 13:43:18,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],although it does not rule out suggests that the PAIN,n/a,168,143,172,149,-1,RO-has_definitional_manifestation,904945-FS1,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA
502568586,7/12/2014 07:14:23,,1321245689,7/12/2014 07:13:34,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],SYMPTOMS due to a large,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 07:51:54,,1321257675,7/12/2014 07:51:16,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],due to,na,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 07:57:28,,1321259648,7/12/2014 07:57:19,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],patient with,da,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 08:35:41,,1321271903,7/12/2014 08:35:09,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",due to large,n/a,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 08:55:07,,1321277886,7/12/2014 08:54:43,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],due to,n/a,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 08:55:36,,1321278003,7/12/2014 08:54:13,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],presented with,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 09:25:43,,1321287944,7/12/2014 09:25:23,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[CAUSES],[CAUSES],due to a large,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 10:02:55,,1321300696,7/12/2014 10:02:15,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],NEUROLOGICAL SYMPTOMS PRIMARY MENINGEAL MELANOMA,n/a,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 10:25:13,,1321307903,7/12/2014 10:24:48,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],due,none,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 10:43:46,,1321313620,7/12/2014 10:43:02,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],due to a large,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 10:50:56,,1321315792,7/12/2014 10:50:10,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 11:18:13,,1321325742,7/12/2014 11:17:31,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH],[ASSOCIATED_WITH],due to a large PRIMARY MENINGEAL MELANOMA,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 12:01:04,,1321339301,7/12/2014 12:00:26,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],due to a large PRIMARY MENINGEAL MELANOMA,n/a,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 13:23:29,,1321365193,7/12/2014 13:23:21,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],presented,N/A,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568586,7/12/2014 13:37:02,,1321369807,7/12/2014 13:36:40,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],due to a large,n/a,66,103,87,129,1,RO-disease_may_have_finding,902605-FS1,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA
502568587,7/12/2014 08:18:45,,1321265955,7/12/2014 08:18:15,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],results,na,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 08:32:33,,1321270975,7/12/2014 08:30:27,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],result of an interaction,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 08:36:44,,1321272198,7/12/2014 08:35:43,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",KINDLED SEIZURES,n/a,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 08:55:50,,1321278104,7/12/2014 08:54:03,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],interaction between,n/a,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 09:01:15,,1321279951,7/12/2014 09:00:30,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],SEIZURES,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 09:30:41,,1321289684,7/12/2014 09:29:44,neodev,1,20929875,USA,MA,Boston,71.174.188.90,[MANIFESTATION],[MANIFESTATION],result an interaction between MYOCLONIC SEIZURE and subsequent kindled seizure.,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 10:15:06,,1321304484,7/12/2014 10:14:49,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],interaction between,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 10:50:20,,1321315639,7/12/2014 10:49:26,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],interaction between,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 11:19:39,,1321326290,7/12/2014 11:18:43,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 12:06:41,,1321340817,7/12/2014 12:05:57,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT] [ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",is the result of an interaction between,n/a,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 13:25:24,,1321365774,7/12/2014 13:25:17,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],of,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 13:43:56,,1321372140,7/12/2014 13:43:43,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[CAUSES],[CAUSES],interaction between,N/A,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 13:47:02,,1321373231,7/12/2014 13:46:16,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],is the result of an interaction between,n/a,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 14:01:41,,1321377814,7/12/2014 14:01:00,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [ASSOCIATED_WITH] [SIDE_EFFECT],"[CAUSES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",is the result of,na,67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568587,7/12/2014 14:22:50,,1321383988,7/12/2014 14:22:01,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],is the result,[MANIFESTATION],67,128,83,145,-1,RO-has_definitional_manifestation,904708-FS1,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE
502568588,7/12/2014 07:24:50,,1321249270,7/12/2014 07:24:12,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[NONE],[NONE],N/A,No relation,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 07:58:50,,1321260096,7/12/2014 07:58:41,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],detected normal,da,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 08:15:57,,1321265097,7/12/2014 08:15:41,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],was not detected,na,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 08:26:15,,1321268639,7/12/2014 08:24:28,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],found in biopsies,N/A,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 09:00:31,,1321279624,7/12/2014 08:59:49,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",it was found,n/a,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 09:21:47,,1321286573,7/12/2014 09:20:27,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],MELANOMAS,N/A,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 09:24:40,,1321287654,7/12/2014 09:24:21,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],found in,N/A,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 09:59:35,,1321299567,7/12/2014 09:58:43,vivatic,1,25451531,GBR,,,83.67.28.193,[NONE],[NONE],N/A,"Two different conditions, no relationship indicated.",63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 10:10:39,,1321303132,7/12/2014 10:10:31,instagc,1,27753923,GBR,,,92.40.74.118,[MANIFESTATION],[MANIFESTATION],"normal melanocytes,",n/a,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 10:40:29,,1321312805,7/12/2014 10:39:27,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],found in situ.,N/A,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 11:12:21,,1321323411,7/12/2014 11:11:43,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,No relation.,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 11:16:41,,1321325085,7/12/2014 11:15:56,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[NONE],[NONE],N/A,"""was not detected""",63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 11:36:59,,1321331475,7/12/2014 11:36:10,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],found in biopsies of,n/a,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 13:24:13,,1321365385,7/12/2014 13:24:05,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],benign,N/A,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568588,7/12/2014 13:26:35,,1321366205,7/12/2014 13:25:48,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was found in,n/a,63,132,89,150,-1,RO-has_manifestation,906090-FS1,"EPH A2 was not detected in normal melanocytes, benign compound NEVI OR ADVANCED MELANOMAS though it was found in 2 of 9 biopsies of MALIGNANT MELANOMA in situ.",NEVI OR ADVANCED MELANOMAS,MALIGNANT MELANOMA
502568589,7/12/2014 07:11:16,,1321244789,7/12/2014 07:10:36,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],four surgical specimens of human OVARIAN normal,N/A,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 07:47:48,,1321256344,7/12/2014 07:46:41,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[LOCATION],[LOCATION],ovarian human cell,na,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 07:57:05,,1321259532,7/12/2014 07:56:47,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[SIDE_EFFECT],[SIDE_EFFECT],immunofluorescence assay.,da,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 08:19:19,,1321266179,7/12/2014 08:19:04,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],recognized,na,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 08:55:54,,1321278158,7/12/2014 08:55:34,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],OVARIAN,n/a,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 09:07:55,,1321282262,7/12/2014 09:07:21,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],did not react,n/a,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 09:14:22,,1321284153,7/12/2014 09:13:17,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],on,N/A,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 10:22:33,,1321306992,7/12/2014 10:21:54,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[OTHER],[OTHER],react,n/a,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 10:25:17,,1321307919,7/12/2014 10:24:53,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[LOCATION],[LOCATION],OVARIAN OVARIES,N/A,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 10:27:51,,1321308722,7/12/2014 10:27:22,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[CONTRAINDICATES],[CONTRAINDICATES],with,none,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 10:57:49,,1321317984,7/12/2014 10:57:10,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],with normal human,N/A,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 11:20:48,,1321326698,7/12/2014 11:20:21,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES,N/A,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 11:48:35,,1321335018,7/12/2014 11:47:16,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],indirect immunofluorescence,n/a,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 13:09:46,,1321360874,7/12/2014 13:08:55,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],did not react,n/a,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568589,7/12/2014 13:26:15,,1321366104,7/12/2014 13:26:06,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],normal,N/A,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097-FS1,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA
502568590,7/12/2014 07:13:02,,1321245326,7/12/2014 07:12:43,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],Like other,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 08:13:44,,1321264591,7/12/2014 08:13:18,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],increased substantially,na,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 08:39:54,,1321273112,7/12/2014 08:39:32,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence of,n/a,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 09:01:58,,1321280277,7/12/2014 08:59:47,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 09:18:25,,1321285428,7/12/2014 09:18:02,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],Like other,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 10:09:36,,1321302826,7/12/2014 10:09:27,instagc,1,27753923,GBR,,,92.40.74.118,[TREATS],[TREATS],ATOPIC DISEASES,n/a,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 10:09:41,,1321302870,7/12/2014 10:09:03,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],Like other such as,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 10:14:18,,1321304222,7/12/2014 10:13:38,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[PREVENTS],[PREVENTS],ATOPIC DISEASES ATOPIC ECZEMA,n/a,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 10:24:35,,1321307754,7/12/2014 10:24:15,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],such as,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 11:02:59,,1321319851,7/12/2014 11:02:21,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the prevalence of,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 11:10:56,,1321322896,7/12/2014 11:10:16,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[IS_A],[IS_A],such as,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 11:23:14,,1321327469,7/12/2014 11:22:47,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],the prevalence of,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 12:02:45,,1321339790,7/12/2014 12:01:05,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION] [SIDE_EFFECT],"[MANIFESTATION]
[SIDE_EFFECT]",the prevalence of increased,n/a,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 12:35:12,,1321348570,7/12/2014 12:34:47,neodev,1,18517457,GBR,,,86.29.147.112,[MANIFESTATION],[MANIFESTATION],such as,N/a,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568590,7/12/2014 13:25:46,,1321365935,7/12/2014 13:25:36,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],asthma,N/A,75,11,88,26,-1,RO-cause_of,900195-FS1,"Like other ATOPIC DISEASES such as asthma and hay fever, the prevalence of ATOPIC ECZEMA has increased substantially over the last 30 years, for reasons largely unknown.",ATOPIC ECZEMA,ATOPIC DISEASES
502568591,7/12/2014 07:22:46,,1321248564,7/12/2014 07:22:20,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],leading therapy in the management of,N/A,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 07:55:19,,1321258932,7/12/2014 07:54:19,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],Replacement therapy using FVIII,na,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 08:13:17,,1321264458,7/12/2014 08:12:57,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PREVENTS],[PREVENTS],the leading,na,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 09:12:45,,1321283744,7/12/2014 09:12:24,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[TREATS],[TREATS],leading therapy,n/a,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 10:12:06,,1321303564,7/12/2014 10:11:59,instagc,1,27753923,GBR,,,92.40.74.118,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is the,n/a,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 10:24:10,,1321307590,7/12/2014 10:23:35,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],FVIII HEMOPHILIA,n/a,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 10:31:28,,1321309927,7/12/2014 10:30:56,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],therapy,none,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 11:03:45,,1321320154,7/12/2014 11:03:03,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[TREATS],[TREATS],is the leading therapy,N/A,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 11:14:08,,1321324097,7/12/2014 11:13:36,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],FVIII is the leading therapy in the management of HEMOPHILIA A,N/A,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 12:00:25,,1321339044,7/12/2014 11:59:59,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],therapy in the management of HEMOPHILIA,n/a,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 13:23:20,,1321365135,7/12/2014 13:22:51,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],HEMOPHILIA,N/A,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 13:37:25,,1321369904,7/12/2014 13:37:03,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],leading therapy,n/a,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 13:45:58,,1321372925,7/12/2014 13:45:44,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[TREATS],[TREATS],leading therapy,N/A,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 13:53:58,,1321375420,7/12/2014 13:53:14,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],leading therapy in the management of,n/a,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568591,7/12/2014 13:59:04,,1321377082,7/12/2014 13:58:28,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],leading therapy,na,76,26,88,31,-1,RO-has_manifestation,906015-FS1,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
502568592,7/12/2014 07:39:12,,1321253871,7/12/2014 07:38:28,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[IS_A],[IS_A],refers to a,na,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 07:59:12,,1321260236,7/12/2014 07:59:02,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],SYSTEMIC INFLAMMATORY,da,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 08:39:10,,1321272886,7/12/2014 08:38:47,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",refers to a,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 09:07:20,,1321282040,7/12/2014 09:06:58,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A],[IS_A],refers to,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 10:09:46,,1321302910,7/12/2014 10:09:37,instagc,1,27753923,GBR,,,92.40.74.118,[PREVENTS],[PREVENTS],SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 10:13:33,,1321303983,7/12/2014 10:13:06,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[IS_A],[IS_A],refers to,N/A,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 10:19:56,,1321305994,7/12/2014 10:19:25,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],refers,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 10:22:56,,1321307088,7/12/2014 10:22:32,neodev,1,18517457,GBR,,,86.29.147.112,[IS_A],[IS_A],refers to a,N/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 11:11:42,,1321323172,7/12/2014 11:11:20,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,N/A,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 11:14:03,,1321324044,7/12/2014 11:13:41,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[IS_A],[IS_A],refers to a,N/A,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 13:10:35,,1321361136,7/12/2014 13:10:18,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],refers to,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 13:14:35,,1321362290,7/12/2014 13:13:57,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[IS_A],[IS_A],refers to a,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 13:25:36,,1321365897,7/12/2014 13:25:26,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],microbial,N/A,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 13:38:04,,1321370099,7/12/2014 13:37:27,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],refers to a,n/a,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568592,7/12/2014 13:42:37,,1321371631,7/12/2014 13:42:19,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],refers to,N/A,19,0,58,6,-1,RO-cause_of,900197-FS1,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502568593,7/12/2014 07:23:42,,1321248918,7/12/2014 07:23:12,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],JOINT EFFUSION joint fluid JOINT,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 07:58:39,,1321260003,7/12/2014 07:58:31,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],reported displacement.,da,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 08:40:41,,1321273389,7/12/2014 08:40:16,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",joint fluid in,n/a,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 08:53:01,,1321277230,7/12/2014 08:51:46,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is related to,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 09:26:10,,1321288053,7/12/2014 09:25:44,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in and around the JOINT,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 09:28:04,,1321288704,7/12/2014 09:26:14,neodev,1,20929875,USA,MA,Boston,71.174.188.90,[LOCATION],[LOCATION],JOINT EFFUSION excessive accumulation fluid around the JOINT,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 09:47:11,,1321295271,7/12/2014 09:46:16,vivatic,1,25451531,GBR,,,83.67.28.193,[LOCATION],[LOCATION],excessive accumulation in and around,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 09:48:02,,1321295464,7/12/2014 09:47:39,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in and around the,n/a,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:07:34,,1321302188,7/12/2014 10:06:56,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],JOINT EFFUSION JOINT,n/a,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:08:23,,1321302470,7/12/2014 10:08:14,instagc,1,27753923,GBR,,,92.40.74.118,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],excessive accumulation,n/a,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:19:34,,1321305890,7/12/2014 10:19:12,neodev,1,18517457,GBR,,,86.29.147.112,[LOCATION],[LOCATION],in and around the,N/a,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:20:25,,1321306154,7/12/2014 10:19:36,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],is,none,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:21:54,,1321306721,7/12/2014 10:20:33,clixsense,1,27812714,NLD,6,Tilburg,84.31.160.155,[OTHER],[OTHER],excessive accumulation joint fluid,n/a,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:49:16,,1321315330,7/12/2014 10:47:36,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[OTHER],[OTHER],around,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568593,7/12/2014 10:54:57,,1321317118,7/12/2014 10:54:12,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],in and around,N/A,26,26,31,40,1,RO-has_finding_site,905403-FS1,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION
502568594,7/12/2014 07:22:58,,1321248633,7/12/2014 07:22:47,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],such as,N/A,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 07:59:00,,1321260148,7/12/2014 07:58:52,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],other hand,da,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 08:16:55,,1321265381,7/12/2014 08:16:28,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],On the other hand induce,na,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 08:23:49,,1321267690,7/12/2014 08:22:21,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],such as,N/A,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 08:29:56,,1321270069,7/12/2014 08:29:35,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PRIMARY SKIN DISEASES PSORIASIS,n/a,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 08:56:40,,1321278385,7/12/2014 08:55:51,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[IS_A],[IS_A],such as,n/a,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 10:02:13,,1321300507,7/12/2014 10:01:39,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],such as,N/A,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 10:08:13,,1321302407,7/12/2014 10:07:51,instagc,1,27753923,GBR,,,92.40.74.118,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DISEASES such,n/a,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 10:23:10,,1321307191,7/12/2014 10:22:45,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],such as,none,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 10:23:31,,1321307331,7/12/2014 10:23:15,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],such as,N/A,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 10:48:41,,1321315196,7/12/2014 10:48:10,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],PRIMARY SKIN DISEASES such as PSORIASIS,N/A,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 11:02:21,,1321319637,7/12/2014 11:01:32,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[IS_A],[IS_A],such as,N/A,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 12:36:00,,1321348784,7/12/2014 12:35:35,neodev,1,18517457,GBR,,,86.29.147.112,[MANIFESTATION],[MANIFESTATION],such as,N/a,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 13:27:28,,1321366521,7/12/2014 13:27:03,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],such as,n/a,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568594,7/12/2014 13:43:18,,1321371921,7/12/2014 13:42:57,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],such as,n/a,18,48,39,57,1,RO-disease_has_primary_anatomic_site,902335-FS1,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS
502568595,7/12/2014 08:33:24,,1321271198,7/12/2014 08:33:03,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in shoulder periARTHRITIS,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 09:02:49,,1321280603,7/12/2014 09:01:23,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],of the,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:07:29,,1321302164,7/12/2014 10:06:21,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,NONE,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:11:24,,1321303372,7/12/2014 10:10:26,vivatic,1,25451531,GBR,,,83.67.28.193,[OTHER],[OTHER],"in three, in two",N/A,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:12:39,,1321303693,7/12/2014 10:12:26,instagc,1,27753923,GBR,,,92.40.74.118,[CONTRAINDICATES],[CONTRAINDICATES],SMALL JOINTS OF THE HANDS periARTHRITIS,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:12:45,,1321303738,7/12/2014 10:12:16,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[LOCATION],[LOCATION],in,N/A,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:23:30,,1321307330,7/12/2014 10:22:50,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[LOCATION],[LOCATION],SMALL JOINTS OF THE HANDS periARTHRITIS,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:27:41,,1321308674,7/12/2014 10:27:20,neodev,1,18517457,GBR,,,86.29.147.112,[LOCATION],[LOCATION],arthritis of the,N/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 10:50:09,,1321315601,7/12/2014 10:49:26,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],"arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS",N/A,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 11:06:28,,1321321216,7/12/2014 11:03:46,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[SYMPTOM],[SYMPTOM],associated with arthritis,N/A,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 12:03:28,,1321339994,7/12/2014 12:02:46,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with arthritis,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 13:11:44,,1321361505,7/12/2014 13:11:02,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],arthritis of the SMALL JOINTS,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 13:28:17,,1321366820,7/12/2014 13:28:04,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],motion,N/A,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 13:36:15,,1321369576,7/12/2014 13:35:46,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568595,7/12/2014 13:44:22,,1321372343,7/12/2014 13:44:10,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,178,227,203,236,1,RO-disease_has_primary_anatomic_site,902259-FS1,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS
502568596,7/12/2014 07:26:39,,1321250023,7/12/2014 07:26:18,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],BLADDER normal BLADDER,N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 08:30:20,,1321270192,7/12/2014 08:29:57,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BLADDER CARCINOMA BLADDER EPITHELIUM.,n/a,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 09:07:55,,1321282270,7/12/2014 09:07:01,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the normal,N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 10:10:25,,1321303067,7/12/2014 10:09:42,vivatic,1,25451531,GBR,,,83.67.28.193,[OTHER],[OTHER],BLADDER BLADDER,N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 10:11:28,,1321303376,7/12/2014 10:11:21,instagc,1,27753923,GBR,,,92.40.74.118,[CAUSES],[CAUSES],human myelomonocytic,n/a,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 10:18:51,,1321305618,7/12/2014 10:18:03,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[OTHER],[OTHER],never,none,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 10:25:40,,1321308039,7/12/2014 10:25:19,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BLADDER BLADDER,N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 10:26:48,,1321308380,7/12/2014 10:26:12,neodev,1,18517457,GBR,,,86.29.147.112,[OTHER],[OTHER],but never with the normal,N/a,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 11:18:42,,1321325996,7/12/2014 11:17:52,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.,N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 11:43:15,,1321333273,7/12/2014 11:42:41,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[PART_OF],[PART_OF],but never with the normal,n/a,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 13:13:55,,1321362083,7/12/2014 13:12:46,clixsense,1,6500439,AUS,2,Ingleburn,115.146.65.99,[OTHER],[OTHER],never with,n/a,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 13:24:57,,1321365627,7/12/2014 13:24:49,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[OTHER],[OTHER],"antigen,",N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 13:46:14,,1321372991,7/12/2014 13:45:59,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[LOCATION],[LOCATION],normal BLADDER EPITHELIUM.,N/A,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 13:52:46,,1321375139,7/12/2014 13:51:59,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],found to react with but never with,n/a,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
502568596,7/12/2014 14:00:11,,1321377426,7/12/2014 13:59:38,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT],[SIDE_EFFECT],never,na,156,112,174,129,1,RO-disease_has_primary_anatomic_site,902019-FS1,"Anti Leu M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with BLADDER CARCINOMA but never with the normal BLADDER EPITHELIUM.",BLADDER EPITHELIUM,BLADDER CARCINOMA
